Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292
Pierce DW, Ponader S, Balakrishnan K, et al.
Key Points:
CC-292 novel small molecule inhibitor with subnanomolar activity against BTK in kinase assays
Additional preclinical data indicated CC-292 anti-tumor activity associated with shortened survival of CLL cells
CLL cell migration and actin polymerization in response to chemokines (CXCL12, CXCL13) impaired with treatment with CC-292
Plasma CCL3 and CCL4 levels markedly diminished by CC-292 treatment
Implications:
- Promising preclinical data of CC-292 lend support for further development
View the original abstract on the ASH website.
